Company intelligence / Profile preview

Domus Diagnostics

Park City, Utah, United Statesdomusdx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Domus Diagnostics has developed a proprietary low-cost, instrument-free molecular diagnostic platform using laminate card and LAMP-based nucleic acid detection. Their lead product—a multiplex at-home or point-of-care test for COVID‑19, Flu A/B, and RSV—has received NIH RADx funding and entered clinical validation. The company aims to achieve regulatory authorizations including FDA EUA and CLIA waiver.

Therapeutic areas: Infectious Diseases
Modalities: DeviceMolecular diagnostic test (Nucleic acid amplification)Isothermal amplification technology
Industry: Molecular Diagnostics

Partnerships

National Institutes of Health (NIH) RADx Tech programCIMIT/NIBIB partnership via grant supportDuke University collaboration/investment

Beyond the preview

Go deeper on Domus Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Domus Diagnostics.

Explore the full profile